Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study
BackgroundCurrent guidelines prioritize the use of Azvudine in Coronavirus Disease 2019 (COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients are still lacking. Here, we aim to assess the prognostic value of eosinopenia in Azvudine-treated COVID-19 patients.Method...
Main Authors: | Xiaomin Wang, Yating Dian, Qian Zhou, Guangtong Deng, Rui Wei, Furong Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1320973/full |
Similar Items
-
Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
by: Manyun Mao, et al.
Published: (2023-10-01) -
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyResearch in context
by: Yuming Sun, et al.
Published: (2023-05-01) -
Immunophenotyping characteristics and outcome of COVID‐19 patients: peripheral blood CD8+T cell as a prognostic biomarker for patients with Nirmatrelvir
by: Yuming Sun, et al.
Published: (2023-09-01) -
Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
by: Yuming Sun, et al.
Published: (2023-08-01) -
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis
by: Yating Dian, et al.
Published: (2024-12-01)